Clinical Trial Update: A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

View source ↗

Summary

Pfizer's Elranatamab study in relapsed/refractory multiple myeloma has completed and posted results. The trial investigated the medicine in patients with relaps…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Status: COMPLETED | Results posted: 2024-04-22